Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Sierra Oncology is betting its future on the phase 3 myelofibrosis drug it picked up from Gilead for a knockdown price. The JAK 1/2 inhibitor underwhelmed in the clinic at Gilead but Sierra has decided to focus its resources on the drug, leading it to search for non-dilutive ways to fund other assets.